PSUR vs PBRER vs DSUR: What Each Periodic Report Is Really For PSUR vs PBRER vs DSUR: What Each Periodic Report Is Really For Context of Pharmacovigilance Reporting Pharmacovigilance is essential in drug development and post-marketing phases, focusing on the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. Regulatory authorities, including the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), mandate periodic safety reporting obligations that ensure continuous monitoring of drug safety. The main periodic reports utilized to fulfill these obligations include…

Designing Efficient Processes for Aggregate Safety Reporting Designing Efficient Processes for Aggregate Safety Reporting In the pharmaceutical and biotechnology industries, effective pharmacovigilance services are essential for ensuring patient safety, regulatory compliance, and optimal drug development strategies. Aggregate safety reporting, including the management of Periodic Safety Update Reports (PSURs), Benefit-Risk Evaluation Reports (PBRERs), and Development Safety Update Reports (DSURs), is a critical component of pharmacovigilance compliance. This article serves as a comprehensive regulatory explainer manual, detailing the relevant regulations, guidelines, and agency expectations surrounding these reports, and how regulatory affairs teams can design efficient reporting processes. Context Aggregate safety reporting plays…

Data Sources You Must Harmonise Before Drafting Periodic Reports Data Sources You Must Harmonise Before Drafting Periodic Reports Context In the domain of pharmacovigilance, the preparation of periodic safety update reports (PSURs), periodic benefit-risk evaluation reports (PBRERs), and development safety update reports (DSURs) is a critical process aimed at ensuring drug safety and compliance with global regulations. The integrity and accuracy of these reports hinge on the harmonization of various data sources. Regulatory Affairs (RA) professionals are tasked with ensuring that the information dedicated to drug safety is comprehensive and meets the expectations set forth by regulatory bodies such as…

Writing Clear Benefit–Risk Sections in PSURs and PBRERs Writing Clear Benefit–Risk Sections in PSURs and PBRERs Context Periodic safety update reports (PSURs), periodic benefit-risk evaluation reports (PBRERs), and development safety update reports (DSURs) are integral components of pharmacovigilance and drug safety regulations. These documents provide essential information regarding the evaluation of a pharmaceutical product’s safety profile over time and are paramount in ensuring ongoing regulatory compliance with health authority expectations. Understanding how to effectively write the benefit-risk sections of these reports is crucial for regulatory affairs professionals, particularly in the context of GVP guidelines established by regulatory authorities like the…

Coordinating Clinical, RA and PV Inputs into DSURs Coordinating Clinical, RA and PV Inputs into DSURs In the pharmaceutical industry, effective coordination among various functional teams is crucial for maintaining compliance with global pharmacovigilance regulations. The Development Safety Update Report (DSUR) is an essential tool that brings together inputs from Clinical, Regulatory Affairs (RA), and Pharmacovigilance (PV) teams. This article will explore the regulatory context, legal and regulatory basis, documentation requirements, approval flow, and common deficiencies associated with preparing DSURs, ensuring compliance with Good Vigilance Practice (GVP) guidelines. Regulatory Context The DSUR is a key component of the periodic safety…

Common Deficiencies Noted by Agencies in Periodic Safety Reports Common Deficiencies Noted by Agencies in Periodic Safety Reports In the pharmaceutical and biotechnology industries, adherence to regulatory requirements is pivotal for ensuring product safety and efficacy. Regulatory Affairs professionals, particularly in Pharmacovigilance (PV), play a critical role in maintaining compliance with periodic safety reporting obligations, specifically in the context of Periodic Safety Update Reports (PSURs), Periodic Benefit-Risk Evaluation Reports (PBRERs), and Development Safety Update Reports (DSURs). Understanding the common deficiencies noted by regulatory agencies is essential for professionals in the sector to mitigate risks and enhance product compliance. This article…

Global Scheduling and Calendar Management for Periodic Reporting Global Scheduling and Calendar Management for Periodic Reporting Context of Pharmacovigilance in Regulatory Affairs Pharmacovigilance is a crucial aspect of regulatory affairs, focusing on the safety and efficacy of pharmaceutical products post-marketing. In an increasingly complex regulatory environment, pharmaceutical companies must adhere to stringent pharmacovigilance regulations to ensure that they monitor, assess, and respond to any adverse effects of their products. Central to this is the process of periodic safety reporting, which includes documents such as the Periodic Safety Update Report (PSUR), Periodic Benefit-Risk Evaluation Report (PBRER), and Development Safety Update Report…

Leveraging Signal Management Outputs in Aggregate Safety Narratives Leveraging Signal Management Outputs in Aggregate Safety Narratives In the dynamic landscape of pharmaceutical development and commercialization, regulatory affairs compliance plays a pivotal role in both ensuring patient safety and maintaining product integrity. This article serves as a comprehensive guide to leveraging signal management outputs in aggregate safety narratives, particularly within the context of the Periodic Safety Update Reports (PSURs), Periodic Benefit-Risk Evaluation Reports (PBRERs), and Development Safety Update Reports (DSURs) in compliance with Good Pharmacovigilance Practices (GVP) guidelines. Context Regulatory affairs compliance pertains to the processes and obligations that pharmaceutical and…

Aligning PSUR/PBRER Content with Labelling and RMP Updates Aligning PSUR/PBRER Content with Labelling and RMP Updates Context Pharmacovigilance is pivotal for ensuring the safety of medicinal products throughout their lifecycle. Regulatory Affairs (RA) professionals must effectively manage compliance regarding Periodic Safety Update Reports (PSURs), Periodic Benefit-Risk Evaluation Reports (PBRERs), and Development Safety Update Reports (DSURs). The interaction of these reports with labeling updates and Risk Management Plans (RMPs) indicates a structured approach to ensure that all safety and efficacy data is accurately communicated to the healthcare community. Legal and Regulatory Basis In an ever-evolving regulatory landscape, it is essential for…

Vendor and Authoring Models for High-Quality Aggregate Reports Vendor and Authoring Models for High-Quality Aggregate Reports In the context of pharmacovigilance, the preparation and submission of high-quality aggregate reports such as Periodic Safety Update Reports (PSURs), Benefit-Risk Evaluation Reports (PBRERs), and Development Safety Update Reports (DSURs) are essential for maintaining drug safety and regulatory compliance. This article outlines the regulatory affairs context for these reports, dives into the relevant guidelines and agency expectations, describes the documentation and review processes, and examines common deficiencies encountered during submissions. Regulatory Affairs Context Regulatory affairs encompass the processes and functions responsible for ensuring that…